Who are Mesenchymal Stem Cells's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, IL-7/IL-15 pre-treated CD19 cells, umbilical cord-mesenchymal stem cells, ACP, PCRA (Intermittent injection), Cord blood.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mesenchymal-stem-cells.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Mesenchymal Stem Cells — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mesenchymal Stem Cells (Mesenchymal Stem Cells) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy. Area: Regenerative Medicine, Immunology.

phase 3 Cell therapy Regenerative Medicine, Immunology Biologic Live · refreshed every 30 min

Target snapshot

Mesenchymal Stem Cells (Mesenchymal Stem Cells) — Ottawa Hospital Research Institute. Mesenchymal stem cells promote tissue repair and modulate immune responses through secretion of anti-inflammatory factors and differentiation into specialized cell types.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mesenchymal Stem Cells TARGET	Mesenchymal Stem Cells	Ottawa Hospital Research Institute	phase 3	Cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
IL-7/IL-15 pre-treated CD19 cells	IL-7/IL-15 pre-treated CD19 cells	jiangjingting	marketed	CAR-T cell therapy	CD19
umbilical cord-mesenchymal stem cells	umbilical cord-mesenchymal stem cells	General Hospital of Shenyang Military Region	marketed	Cell therapy
ACP	ACP	Istituto Ortopedico Rizzoli	marketed	Cell therapy / Regenerative medicine product
PCRA (Intermittent injection)	PCRA (Intermittent injection)	Örebro University, Sweden	marketed	Cancer vaccine / Autologous cell therapy
Cord blood	Cord blood	New York Medical College	marketed	Hematopoietic stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy class)

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2 drugs in this class
Bone Therapeutics S.A · 1 drug in this class
DiscGenics, Inc. · 1 drug in this class
Celavie Bioscences, LLC · 1 drug in this class
China Spinal Cord Injury Network · 1 drug in this class
City of Hope Medical Center · 1 drug in this class
Brainstorm-Cell Therapeutics · 1 drug in this class
Dr. Grant M. Pagdin · 1 drug in this class
FDA Office of Orphan Products Development · 1 drug in this class
Biosolution Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mesenchymal Stem Cells — Competitive Intelligence Brief. https://druglandscape.com/ci/mesenchymal-stem-cells. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing